Table 2.
In-hospital outcomes
| SAVR group | TAVI group | 95% CI | |
|---|---|---|---|
| (N = 580) | (N = 1134) | ||
| All-cause death | 13 (2.2%) | 7 (0.6%) | 1.6 (0.3–2.9) |
| Stroke | 12 (2.1%) | 32 (2.8%) | − 0.8 (− 2.3–0.8) |
| Disabling stroke | 5 (0.9%) | 21 (1.9%) | − 1.0 (− 2.1–0.1) |
| Major Bleeding | 416 (72%) | 222 (20%) | 52.1 (47.8–56.5) |
| Newly diagnosed AF | 153 (26%) | 52 (4.6%) | 21.8 (18–25.6) |
| Pacemaker implantation | 14 (2.4%) |
92 (8.1%) SAPIEN3 47 (6.0%) Evolut R/ Pro/Pro Plus 45 (13.1%) |
− 5.7 (− 7.7–3.7) |
| Acute kidney injury | 32 (5.5%) | 34 (3.0%) | 2.5 (0.4–4.6) |
| Major vascular complications | 20 (3.4%) | 26 (2.3%) | 1.2 (− 0.6–2.9) |
| ICU stay after procedure (days) | 3 (2–4) | 1 (1–2) | – |
| Hospital stay after procedure (days) | 16 (13–23) | 8 (7–12) | – |
The definitions of the outcome measures were described in the Supplemental Appendix B
ICU intensive care unit, AF atrial fibrillation